BBLGNasdaq

Bone Biologics Corp

Healthcare·Immunology·Commercial·Burlington, MA, United States
ImmunologyMetabolicDermatology

Bone Biologics Corp (BBLG): 61 pipeline candidates. Updated within the last hour.

10.0/10

BioSniper Score

2-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health9.9

D/E 0.07 · 0% dilution

Pipeline MaturityN/A

N/A

Pipeline Breadth10.0

61 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Bone Biologics Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$2.5M

Cash

Quarterly Burn

$804K

Runway

Revenue

Pipeline (61 candidates)

Showing 10 of 61 candidates. Sign up for full pipeline.

Institutional Holdings

Source: SEC Form 13F · as of Dec 2025

Institutional holders

3

Total value held

$32K

HolderSharesValue
two sigma investments, lp11,083$16K
citadel advisors llc10,844$16K
bank of america corp /de/14$20
·2 FDA decisions·CEO: Mr. Jeffrey Frelick

Frequently asked questions

How many drug candidates are in Bone Biologics Corp's pipeline?

Bone Biologics Corp (BBLG) has 61 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Bone Biologics Corp's market capitalization?

Bone Biologics Corp's market capitalization is approximately $2.5M.

Who is the CEO of Bone Biologics Corp?

Mr. Jeffrey Frelick is the chief executive officer of Bone Biologics Corp (BBLG).

Get the full picture on Bone Biologics Corp

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.